SWOG clinical trial number
SWOG-9320
Study of ProMACE-CytaBOM with Trimethoprim Sulfamethoxazole, Granulocyte Colony Stimulating Factor (G-CSF) and Antiretroviral Therapy in Patients with AIDS Related Lymphoma, Phase II
Closed
Phase
Accrual
100%
Published
Research committees
Lymphoma
Treatment
Radiation Therapy
ProMACE-CytaBOM
RT
Eligibility Criteria Expand/Collapse
Biopsy proven, non-Hodgkin's Groups D-H & J; prior diagnosis of AIDS or HIV pos.; bidimen. meas.; pts w/primary CNS lymphoma are ineligible; no prior chemo or RT; no hx of cardiac impairment.
Publication Information Expand/Collapse
2003
Phase II study of pro-MACE CytaBOM with trimethoprim sulfamethoxazole, granulocyte colony stimulating factor (G-CSF) and antiretroviral therapy in patients with AIDS related non-Hodgkin's lymphoma (AIDS-NHL), (S9320)
1999
Frequent expression of hte tumor necrosis factor receptor associated factor-1 in LMP1-positive post transplant lymphoproliferative disease and HIV-associated lymphomas
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase